Registry of Patients With Suspected Amyloidosis in Heart Failure

Heart Failure Clinical Trial

— Regamic  

Official title:

Registry of Patients With Suspected Amyloidosis in Heart Failure: Regamic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05176548
• Other study ID #: REGAMIC-1450-N-21
• Status: Recruiting
• Start date: January 15, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: February 2023
• Source: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Contact: Oscar Aramburu-Bodas, MD, PhD
• Phone: + 34 654038491
• Email: OSCARAB2000[@]GMAIL.COM
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Observational multicenter registry of cohorts with follow-up.

Patients with heart failure, age ≥ 18 years, with clinical suspicion of cardiac amyloidosis and any LVEF value, treated in the field of Internal Medicine.

Initially, a duration of two years was established to recruit at least 150 patients in the group with AC, and a follow-up of two years.

Upon completion of the two years of follow-up, the continuity or completion of the registry will be assessed.

Description:

Observational, cohort study with a duration of two years to recruit at least 150 patients in the group with CA, and a follow-up of two years. The investigators estimate a sample size of at least 150 patients in the Group 1 (CA confirmed), and a total of 450 patients.

The primary objectives of this study are:

• To evaluate differential characteristics between two groups of patients with Heart

Failure with clinical suspicion of Cardiac Amyloidosis (CA):

• Group 1: Patients in whom CA is confirmed.

• Group 2: Patients in whom CA is ruled out.

• Clinical, laboratory, electrocardiographic, echocardiographic characteristics, and other studies (MRI, biopsies, etc.) will be compared between both groups.

The secondary objectives are:

• To evaluate the clinical and complementary test data on which the suspicion of the diagnosis of AC has been based.

• To identify prognostic differences between both groups by comparing readmission rates, mortality and other events of patients with CA and without CA in a period of two years.

The patients included in the study are elderly patients, of both genders, with heart failure, who have undergone an echocardiogram in the last 24 months, with a clinical suspicion of amyloidosis.

All patients who meet inclusion criteria will be included from January 2022 to December 2023.

The following studies are performed on each patient:

• Clinical, laboratory, electrocardiographic, echocardiographic.

• Bone-cardiac scintigraphy.

• Laboratory test to rule out monoclonal protein.

• The number of readmissions, emergency room visits, and mortality in the 24 months following their inclusion will be recorded.

A descriptive analysis of the data and a comparative analysis will be made in relation to different variables. The association of different variables with readmission and mortality data will be assessed using univariate and multivariate analysis. An analysis of survival curves will also be performed using the Kaplan-Meier method using the log-rank test.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

• Age = 18 years.

• Both genders.

• Heart Failure (2021 European Society of Cardiology criteria)

• Any LVEF value.

• Outpatients or hospitalized patients in Internal Medicine Units

• Patients with suspicion criteria proposed by the European Society of Cardiology:

• Ventricular hypertrophy = 12 mm

And one or more of the following criteria:

• Heart failure in = 65 years

• Aortic stenosis in = 65 years

• Hypotension or Normotensive if previously hypertensive

• Sensory involvement, autonomic dysfunction

• Peripheral polyneuropathy

• Proteinuria

• Skin bruising (eg, periorbital purpura)

• Bilateral carpal tunnel syndrome

• Ruptured biceps tendon

• In CMR: Subendocardial / transmural late gadolinium enhancement (LGE), or increased extracellular volume (ECV)

• In ECO: Reduced longitudinal strain with apical sparing

• Reduced QRS voltage to mass ratio

• Pseudo Q waves on ECG

• Atrioventricular conduction disease

• Possible family history of ATTRv

EXCLUSION CRITERIA:

• Refusal to participate in the registry

Related Conditions & MeSH terms

• Amyloidosis
• Heart Failure

Intervention

Diagnostic Test:
• Bone-cardiac scintigraphy
Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene

Locations

Country	Name	City	State
Spain	Hospital Universitario Virgen Macarena	Sevilla

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differential characteristics between two groups	Number of biopsies performed between both groups.	Up to two years
Secondary	Prognostic differences between both groups	Readmission rate of patients with AC and without AC in a period of two years.	Up to two years
Secondary	Prognostic differences between two groups	Mortality rate of patients with AC and without AC in a period of two years.	Up to Two years